HEMATOLOGY
Comprehensive disease testing
A BioPharma Diagnostics collaboration enables access to the hematological disease testing capabilities of Mayo Clinic Laboratories, including:
- Acute leukemias
- Amyloidosis
- Benign disorders
- Coagulation disorders
- Lymphoid disorders
- Myeloma
News and updates
The latest
We are excited to announce that registration is now open for the 2026 Mayo Clinic Classical Hematology Conference: Nonmalignant Hematology and Bleeding and Thrombotic Disorders.
Xinjie Xu, Ph.D., co-director of Mayo's Genetics and Genomics Laboratory, explains Mayo Clinic Laboratories' updated approach to testing for risk stratification of patients newly diagnosed with plasma cell proliferative disorders, such as multiple myeloma. Based on recently published data, the new testing algorithms focus on use of fluorescence in situ hybridization (FISH) panels, rather than chromosome studies.
In this month’s “Hot Topic,” James Hoyer, M.D., discusses the importance of using a control tube during osmotic fragility testing.
Min Shi, M.D., Ph.D., a hematologist and co-director of Mayo Clinic's Flow Cytometry Laboratory, explains recent updates to the B-cell lymphoblastic leukemia minimal residual disease flow cytometry assay. This test is used to identify minimal residual disease in patients with a previously confirmed diagnosis of B-cell lymphoblastic leukemia who have completed chemotherapy, immunotherapy or bone marrow transplantation.
Matt Millen, ex-pro NFL player, who played on four Super Bowl-winning teams underwent a nearly six-year medical journey in search for answers. Finally, he was diagnosed with amyloidosis using a new testing methodology at Mayo Clinic.
Mayo Clinic Laboratories provides evaluation and consultation for the diagnosis and treatment of patients with hereditary and acquired hematologic disorders.
In this month’s “Hot Topic,” Curtis Hanson, M.D., will discuss the use of laboratory-based prognostic markers in patients with chronic lymphocytic leukemia (CLL). He will also highlight the importance of molecular analyses for IGHV and TP53 sequencing in these patients.
Curtis Hanson, M.D., discusses the importance of detecting immunoglobulin heavy-chain variable region gene (IGHV) when acquiring prognostic and potentially therapeutic information in chronic lymphocytic leukemia (CLL) patients in CAP TODAY.
The current diagnostic tools in a pathologist’s arsenal sometimes cannot provide a clear distinction between primary mediastinal large B-cell lymphoma (one of the few lymphomas more common in younger women) and diffuse large B-cell lymphoma, the most common type of non-Hodgkin’s lymphoma overall.
In this month’s “Hot Topic,” Rajiv Pruthi, M.B.B.S., will discuss different types of hemophilia along with their pathologic basis. He will also cover various types of factor assays such as one stage and chromogenic factor assays for diagnosis and their role in management of hemophilia.
In this month’s “Hot Topic,” Brad Karon, M.D., Ph.D., describes how pseudohyperkalemia has many causes, from collection techniques, processing, and even transport. This presentation focuses on the various preanalytic and analytic causes of pseudohyperkalemia and what you as a phlebotomist can do to prevent it.
The diagnosis of Myeloproliferative Neoplasm (MPN) must include an integrated approach and combine the clinical findings with laboratory results. In our latest “Hot Topic,” Rong He, M.D., discusses the subclassification of MPNs and the use of JAK2, CALR, and MPL mutational analysis in diagnosis and prognosis.
Flow cytometric immunophenotyping method can be useful in assessing myeloid dysmaturation. In this “Hot Topic,” Dragon Jevremovic, M.D., Ph.D., describes a new flow cytometric test to detect aberrant patterns of expression in the diagnosis of myelodysplastic syndrome.